This Pharma Company Just Hit a 'Milestone'!

[Trade of the Day Wake-Up Watchlist] Good morning, Wake-Up Watchlisters! Happy [national pasta day]( Before you prep your noodle maker for the big day take a seat and let’s review what’s happening in the premarket. It’s still earnings season with big names putting out reports this week. Bank of America (BAC) kicked things off this morning topping analysts’ estimates and posting a positive surprise of $0.81 a share vs the expected $0.78. Still to come are Charles Schwab, (SCHW), Tesla (TSLA), Netflix (NFLX), and AT&T (T) among others. This week the Biden administration will be revealing the next step in its plan to reduce gasoline prices and China will release its third-quarter GDP figures, providing a key update on the second-largest economy in the world. The markets are green across the board, here’s hoping they stay that way! [The War Room is having a FREE Open House from Oct. 24-28 (9-4pm ET)]( Last time we did this, attendees had a chance to cash in 15 winners in five days... including an overnight double! FOR FREE! No catch... no delayed billing... no BS. [Click here to sign up for the event now!]( Now, let’s take a look at the top-moving stocks this morning. Acorda Therapuetics Inc. (Nasdaq: ACOR) Acorda Therapuetics Inc. is up 62.15% premarket. The company announced this morning that a three-judge panel has come to a decision in a dispute over licensing royalties relating to MS treatment, AMPYRA (dalfampridine). Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes PLC (Nasdaq: ALKS). Also, Acorda will no longer have to pay Alkermes any royalties for sales, licensing, and supply of AMPYRA. Leadership is confident this settlement will allow them to reduce the price of the treatment and help even more of the estimated 2.5 million people in the world who live with MS. Milestone Pharmacueticals (Nasdaq: MIST) Milestone Pharmaceuticals is up 36.16% premarket. This jump comes after the announcement this morning of positive results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray. The treatment promises to provide more affordable and accessible relief for patients with a type of abnormal heart rhythm called [Paroxysmal Supraventricular Tachycardia]( (PSVT). This arrythmia affects an estimated 2 million people in the United States alone. We see pharmaceutical and healthcare companies like Milestone and Acorda making huge premarket moves all the time. Our friend and investing mastermind, Alexander Green has found a healthcare company with a technology he is calling [“the most incredible investment opportunity in 37 years.”]( [Get in before the stock pops in the premarket and ends up on this list!]( [This NEW Electric Vehicle Stock Could Help Fund Your Retirement]( Its car is faster than super-cars like Ferrari's F8, McLaren's 720S and Porsche's 911 Turbo. Yet it's 100% electric. [Discover the new $25 startup that could be the next EV giant.]( NuCana PLC (Nasdaq: NCNA) NuCana PLC is down 27.82% premarket. The biotechnology company has been working on a treatment for tumors in melanoma patients and [presented promising data]( at the European Society of Medical Oncology (ESMO) annual meeting last month. This led some analysts including Zacks to raise their estimates for the stock. There has been no news break yet, but something must have pulled the rug out from under everyone’s feet and caused the stock to nosedive this morning. Alfi Inc. (Nasdaq: ALF) Alfi Inc. down 16.48% premarket. The digital advertising company founded in 2018 and just listed on the Nasdaq a year and a half ago, filed for Chapter 7 bankruptcy. Plagued by lawsuits and investigations for most of the time it’s been on the market, the company is now down to the last 5 employees. This may be the end for Alfi Inc. but bankruptcies in general are down compared to last year according to the Administrative Office of the U.S. Courts. [Once again, The War Room is opening its doors to the public for a FREE Open House from Oct. 24-28 (9-4pm ET)]( As you can see in the table above, this does not happen often, but when it does attendees have had incredible opportunities to lock in wins, including overnight doubles. For FREE! [Don’t miss your chance, sign up now and join us for a FREE week.]( Those are the top market movers today. Happy trading! The Wake-Up Watchlist Research Team [Don't Believe Us? (See for Yourself FREE)]( [Open House]( Matthew G. just said his account went from $65K... to $100,000... in just two months. But don't take our word for it... Get a full week of LIVE picks (the last time we did this, we hit 15 winners in five days... including an overnight DOUBLE). [Join Our One-Week Preview for FREE!]( [Monument Traders Alliance] Monument Traders Alliance You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, [click here](. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 [Website]( | [Privacy Policy]( Keep the emails you value from falling into your spam folder. [Whitelist Trade of the Day](. © 2022 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.